

ALEXION PHARMACEUTICALS INC

Form 8-K

December 18, 2003

---

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported) December 18, 2003

**ALEXION PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in its Charter)

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 8-K

**Delaware**  
(State or Other Jurisdiction)

**0-27756**  
(Commission

**13-3648318**  
(IRS Employer

of Incorporation)

File Number)

Identification No.)

**352 Knotter Drive, Cheshire, CT**  
(Address of Principal Executive Offices)

**06410**  
(Zip Code)

Registrant's telephone number, including area code: (203) 272-2596

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

---

**Item 5. Other Events and Regulation FD Disclosure**

On December 18, 2003, the Company announced its entry into a collaborative agreement with XOMA Ltd. for the development and commercialization of a rationally designed human c-MPL agonist antibody to treat chemotherapy-induced thrombocytopenia. A copy of the press release issued by the Company relating thereto is furnished herewith as Exhibit 99.1.

**Item 7. Financial Statements and Exhibits.**

**(c) Exhibits.**

99.1 Press Release dated December 18, 2003.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALEXION PHARMACEUTICALS, INC.

Date: December 18, 2003

By:

/s/ DAVID W. KEISER

---

Name:

David W. Keiser

Title:

President and Chief Operating Officer